LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Repeated microdosing of LSD (8 to 20 μg) may help improve daily mood, specifically increasing feelings of connection, creativity, and energy in people with major depressive disorder.
External link. We are not responsible for the content.
Read more ↗More From Microdosing Institute
Altered ‘state’ vs Altered ‘sense of self’
Psychedelic culture has given us a powerful image of transformation: the self dissolves, the familiar world disappear...
Citizen Science x Phenomenology
Journaling, editing, reflecting, integrating – all remain valid when formalising your anecdotal report, to make sense...
Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What f...
Latest News
What’s the difference between recreational and therapeutic psychedelic use? 5 Questions with experimental psychologist Harriet de Wit
De Wit discusses the difficulty of finding out what a drug does, outside of its context.
World Ayahuasca Forum Brings Ancestral Intelligence to Spain
PLUS, an interview with an iconic Grateful Dead artist, ayahuasca and loneliness, and Puerto Rico's executive order. ...
The Psychedelic Future We Were Promised
This Week's Sunday Insider: Why the Psychedelic Future Never Arrived.
Weekly Psychedelic Policy Briefing – August 14, 2026
The FDA has finalized guidance on clinical investigations into psychedelic-assisted therapies and contract research o...
Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval
Plus: Pharmaceutical giant Eli Lilly makes a psychedelics acquisition; Cardiovascular safety is top of mind for psych...
9 Questions I'm Obsessed With About Psychedelics Right Now
Welcome to The Psychedelic Blog. Bestselling essayist & Psychedelic cultural analyst examining how altered states sha...